Park Jonghyuck
Pharmaceutical Sciences, College of Pharmacy and Spinal Cord and Brain Injury Research Center, University of Kentucky, USA.
Biomed J Sci Tech Res. 2022 Jul;45(3):36467-36470. doi: 10.26717/bjstr.2022.45.007202. Epub 2022 Jul 29.
Neuroinflammation is a key secondary event after spinal cord injury (SCI) and can increase barriers to regeneration, leading to various neurological disorders. Infiltrated hematogenous innate immune cells into the injured site are considered the main effector cells of the inflammatory responses after SCI. Glucocorticoids were the standard of care for spinal cord trauma for years due to their anti-inflammatory properties yet were also associated with unwanted side effects. While the administration of glucocorticoids is controversial, immunomodulatory strategies that limit inflammatory responses provide the potential therapeutic approaches to promote functional regeneration following SCI. Herein, we will discuss emerging therapeutic strategies to modulate inflammatory responses to enhance nerve recovery after spinal cord trauma.
神经炎症是脊髓损伤(SCI)后的一个关键继发性事件,会增加再生障碍,导致各种神经障碍。浸润到损伤部位的血源性固有免疫细胞被认为是脊髓损伤后炎症反应的主要效应细胞。多年来,糖皮质激素因其抗炎特性一直是脊髓创伤的标准治疗药物,但也会带来不良副作用。虽然糖皮质激素的使用存在争议,但限制炎症反应的免疫调节策略为促进脊髓损伤后的功能再生提供了潜在的治疗方法。在此,我们将讨论调节炎症反应以促进脊髓创伤后神经恢复的新兴治疗策略。